Literature DB >> 19996335

The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.

Jeffrey J Swigris1, Frederick S Wamboldt, Juergen Behr, Roland M du Bois, Talmadge E King, Ganesh Raghu, Kevin K Brown.   

Abstract

RATIONALE: The response characteristics of the 6 minute walk test (6MWT) in studies of idiopathic pulmonary fibrosis (IPF) are only poorly understood, and the change in walk distance that constitutes the minimum important difference (MID) over time is unknown.
OBJECTIVES: To examine changes over time in distance walked (ie, 6MWD) during the 6MWT and to estimate the change in distance that constitutes the MID in patients with IPF.
METHODS: Data from a recently completed trial that included subjects with IPF who completed the 6MWT, Saint George's Respiratory Questionnaire (SGRQ) and forced vital capacity (FVC) at 6 and 12 months were used to examine longitudinal changes in 6MWD. Both anchor- and distribution-based approaches as well as linear regression analyses were used to determine the MID for 6MWD. The SGRQ Total score and FVC were used as clinical anchors. MAIN
RESULTS: Among 123 subjects alive and able to complete the 6MWT at both follow-up time points, 6MWD did not change significantly over time (378.1 m at baseline vs 376.8 m at 6 months vs 361.3 m at 12 months, p=0.5). The point estimate for the 6MWD MID was 28 m with a range of 10.8-58.5 m.
CONCLUSION: In a group of patients with IPF with moderate physiological impairment, for those alive and able to complete a 6MWT, 6MWD does not change over 12 months. At the population level, the MID for 6MWD appears to be approximately 28 m. Further investigation using other anchors and derivation methods is required to refine estimates of the MID for 6MWD in this patient population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19996335      PMCID: PMC3144486          DOI: 10.1136/thx.2009.113498

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  32 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

3.  Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.

Authors:  Ganesh Raghu; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Roland M du Bois; Joseph A Lasky; Michiel Thomeer; James P Utz; Rezaul K Khandker; Lawrence McDermott; Saeed Fatenejad
Journal:  Am J Respir Crit Care Med       Date:  2008-07-31       Impact factor: 21.405

4.  Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

Authors:  E F Juniper; G H Guyatt; A Willan; L E Griffith
Journal:  J Clin Epidemiol       Date:  1994-01       Impact factor: 6.437

Review 5.  Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy.

Authors:  M Selman; T E King; A Pardo
Journal:  Ann Intern Med       Date:  2001-01-16       Impact factor: 25.391

6.  Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia.

Authors:  Tam Eaton; Pam Young; David Milne; Athol U Wells
Journal:  Am J Respir Crit Care Med       Date:  2005-01-07       Impact factor: 21.405

7.  The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure.

Authors:  G H Guyatt; M J Sullivan; P J Thompson; E L Fallen; S O Pugsley; D W Taylor; L B Berman
Journal:  Can Med Assoc J       Date:  1985-04-15       Impact factor: 8.262

8.  Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia.

Authors:  Kevin R Flaherty; Jeanette A Mumford; Susan Murray; Ella A Kazerooni; Barry H Gross; Thomas V Colby; William D Travis; Andrew Flint; Galen B Toews; Joseph P Lynch; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2003-05-28       Impact factor: 21.405

9.  Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends.

Authors:  Panagiota I Latsi; Roland M du Bois; Andrew G Nicholson; Thomas V Colby; Danai Bisirtzoglou; Ageliki Nikolakopoulou; Srihari Veeraraghavan; David M Hansell; Athol U Wells
Journal:  Am J Respir Crit Care Med       Date:  2003-06-05       Impact factor: 21.405

10.  Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives.

Authors:  Jeffrey J Swigris; Anita L Stewart; Michael K Gould; Sandra R Wilson
Journal:  Health Qual Life Outcomes       Date:  2005-10-07       Impact factor: 3.186

View more
  40 in total

Review 1.  Update in diffuse parenchymal lung disease 2011.

Authors:  Tracy R Luckhardt; Joachim Müller-Quernheim; Victor J Thannickal
Journal:  Am J Respir Crit Care Med       Date:  2012-07-01       Impact factor: 21.405

Review 2.  Subclinical interstitial lung disease: why you should care.

Authors:  Tracy J Doyle; Gary M Hunninghake; Ivan O Rosas
Journal:  Am J Respir Crit Care Med       Date:  2012-02-23       Impact factor: 21.405

3.  Interstitial lung abnormalities and reduced exercise capacity.

Authors:  Tracy J Doyle; George R Washko; Isis E Fernandez; Mizuki Nishino; Yuka Okajima; Tsuneo Yamashiro; Miguel J Divo; Bartolome R Celli; Frank C Sciurba; Edwin K Silverman; Hiroto Hatabu; Ivan O Rosas; Gary M Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  2012-01-20       Impact factor: 21.405

4.  Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project.

Authors:  Marisa Couluris; Brent W Kinder; Ping Xu; Margaret Gross-King; Jeffrey Krischer; Ralph J Panos
Journal:  Lung       Date:  2012-07-19       Impact factor: 2.584

5.  The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis.

Authors:  Jeffrey J Swigris; Meilan Han; Rekha Vij; Imre Noth; Eric L Eisenstein; Kevin J Anstrom; Kevin K Brown; Diane Fairclough
Journal:  Respir Med       Date:  2012-07-15       Impact factor: 3.415

6.  A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

Authors:  David A Zisman; Marvin Schwarz; Kevin J Anstrom; Harold R Collard; Kevin R Flaherty; Gary W Hunninghake
Journal:  N Engl J Med       Date:  2010-05-18       Impact factor: 91.245

7.  Cardiorespiratory function before and after aerobic exercise training in patients with interstitial lung disease.

Authors:  Randall E Keyser; Joshua G Woolstenhulme; Lisa M K Chin; Steven D Nathan; Nargues A Weir; Gerilynn Connors; Bart Drinkard; James Lamberti; Leighton Chan
Journal:  J Cardiopulm Rehabil Prev       Date:  2015 Jan-Feb       Impact factor: 2.081

8.  Six Minute Walk Test: A Tool for Predicting Mortality in Chronic Pulmonary Diseases.

Authors:  Mp Swathi Karanth; Nilkanth Tukaram Awad
Journal:  J Clin Diagn Res       Date:  2017-04-01

Review 9.  Clinical use of biomarkers of survival in pulmonary fibrosis.

Authors:  Michiel Thomeer; Jan C Grutters; Wim A Wuyts; Stijn Willems; Maurits G Demedts
Journal:  Respir Res       Date:  2010-06-28

Review 10.  Genetics and early detection in idiopathic pulmonary fibrosis.

Authors:  Rachel K Putman; Ivan O Rosas; Gary M Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  2014-04-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.